abstract |
This application discloses novel cyanoguanidines of the formula (I) wherein A is selected from -C(=O)-, -S(=O)2-, -C(=S)-, and -P(=O)(R5)-, wherein R5 is selected from C1-6-alkyl, C1-6-alkoxy, and hydroxy; B is selected from a single bond, -O-, -NR6- and -C(=O)-NR6-, wherein R6 is selected from hydrogen, optionally substituted C1-12-alkyl, optionally substituted C1-12-alkenyl, optionally substituted aryl, optionally substituted heterocyclyl, and optionally substituted heteroaryl; and m is an integer of 0-12 and n is an integer of 0-12, wherein the sum m+n is 1-20; and R1 is selected from optionally substituted heteroaryl; and pharmaceutically acceptable salts thereof, and prodrugs thereof. The compounds are usefuld for use as a medicament for the treatment of a disease or a condition caused by an elevated level of nicotinamide phosphoribosyltransferase (NAMPRT). |